Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Total Liabilities (2016 - 2025)

Karyopharm Therapeutics' Total Liabilities history spans 14 years, with the latest figure at $401.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 14.53% year-over-year to $401.3 million; the TTM value through Dec 2025 reached $401.3 million, up 14.53%, while the annual FY2025 figure was $401.3 million, 14.53% up from the prior year.
  • Total Liabilities reached $401.3 million in Q4 2025 per KPTI's latest filing, up from $365.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $401.3 million in Q4 2025 to a low of $314.5 million in Q1 2021.
  • Average Total Liabilities over 5 years is $364.8 million, with a median of $370.7 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 49.74% in 2021, then dropped 10.66% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $385.0 million in 2021, then decreased by 2.64% to $374.8 million in 2022, then increased by 0.48% to $376.6 million in 2023, then dropped by 6.96% to $350.4 million in 2024, then grew by 14.53% to $401.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Total Liabilities are $401.3 million (Q4 2025), $365.5 million (Q3 2025), and $343.8 million (Q2 2025).